Visit: www.aicr.org

BREAST CANCER RESEARCH

Breast cancer research we have recently funded at leading universities, cancer centers, and research laboratories nationwide with the help of our donors.

EB 1089/Vitamin D3 and Radiation in Breast Tumor Cells
David A. Gerwirtz, PhD
Virginia Commonwealth University
Dr. Gerwirtz is utilizing the combination of the active form of vitamin D and its analog with radiation to improve the treatment of breast cancer and prevent tumor regrowth due to the generation of reactive oxygen species.
(Jan 1, 2007 – Dec 31, 2008)

Role of Apple in the Prevention of Cancer
Rui Hai Liu, PhD
Cornell University
Dr. Liu is testing the preventive effect of apple phytochemicals against mammary cancer.
(Jan 1, 2007 – Dec 31, 2008)

Chemopreventive Modulation of the Mammary Stromal Vascular Cell by Conjugated Linoleic Acid
Patricia Masso-Welch, PhD
University of Buffalo
Dr. Masso-Welch’s research studies how conjugated dietary fatty acids influence stromal cells to inhibit blood vessel growth in rat mammary tumors.
(Jan 1, 2007 – Dec 31, 2008)

Selenium and Osteoblast Involvement in Breast Cancer Metastases in Bone
Andrea M. Mastro, PhD
The Pennsylvania State University
Dr. Mastro will investigate how selenium affects the interaction of osteoblasts and breast cancer cells.
(Jan 1, 2007 – Dec 31, 2008)

Green Tea Inhibition of Epithelial to Mesenchymal Transition of Breast Cancer Cells
Gail E. Sonenshein, PhD
Boston University School of Medicine
Dr. Sonenshein is studying how green tea polyphenols block the transition of human breast cancer cells from epithelial to mesenchymal in animal models.
(Jan 1, 2007 – Dec 31, 2008)

Prevention of Metastatic Breast Cancer Using a Novel Vitamin E Analog
Emmanuel T. Akporiaye, PhD
University of Arizona
Dr. Akporiaye has developed a novel form of vitamin E, alpha-tocopheryloxyacetic acid (a-TEA). Vesiculated a-TEA (Va-TEA) is more water-soluble and more clinically relevant. The goal of this study is to employ Va-TEA in combination with an immune cells known as the dendritic cell (DC) to destroy metastatic breast cancer and to establish immunity.
(Jul 1, 2007 – Jun 30, 2009)

Use of Green Tea Polyphenol, Epigallocatechin-3-Gallate, as a Novel Treatment for Trastuzumab Resistant Breast Cancer
Nora Mineva, PhD (transferred from Sean Eddy, PhD)
Boston University School of Medicine
Trastuzumab has been used in clinical setting to block the Her-2/neu activity. This postdoctoral application will focus on EGCG and other green tea polyphenols as sensitizers and as effective agents in Her2/neu-resistant breast cancer cells. A mechanistic insight of their efficacy will be sought by examination of the EGFR-mediated signaling pathways.
(Jul 1, 2007 – Sept 1, 2009)

Meat Mutagens and Related Polymorphisms and Risk of Breast Cancer in Women
Eunyoung Cho, ScD
Harvard School of Public Health
The aim of this new proposal is to evaluate the role of meat intake on breast cancer, using data from the Nurses’ Health Study, with emphasis on the major mutagenic heterocyclic amines from prepared meat and breast cancer hormone receptors. The findings will increase understanding of the role of meat mutagens in breast carcinogenesis as this area of research is largely unexplored.
(Jan 1, 2008 – Dec 31, 2009)

Effects of LLSO and LLHOSO on the Progression of Breast Cancer
Young H. Ju, PhD
Virginia Polytechnic Institute and State University
Dr. Ju will study the effects of low linolenic soy oil (LLSO) and low linolenic high oleic soy oil (LLHOSO) on transformation of a pre-malignant human breast cancer cell line in vitro and in vivo as xenografts. The oils are low in trans fatty acids and in addition to their beneficial effects in cardiovascular disease could also be beneficial in prevention and growth of breast cancer.
(Jan 1, 2008 – Dec 31, 2009)

Chemoprevention of Her-2 Positive Breast Cancer by Red Wine Phytochemicals
Nameer B. Kirma, PhD
University of Texas Health Science Center at San Antonio
Dr. Kirma will study the inhibition of breast cancer risk by red wine phytochemicals due to suppression of Her-2 oncogene and Her-2 signaling in adult mice and determine whether aromatase inhibitors in red wine given during prepuberty increase breast cancer risk.

Published on January 20, 2011

Powered by Convio
nonprofit software